Response to paclitaxel and carboplatin in metastatic salivary gland cancer: A case report

Background Malignant tumors of the salivary gland are rare entities that are treated primarily by surgical resection. For patients with recurrent or unresectable disease, options include radiation therapy or chemotherapy; however, responses are few and of short duration. Patients with metastatic dis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Head & neck 2002-04, Vol.24 (4), p.406-410
Hauptverfasser: Ruzich, Janet C., Ciesla, Marlyn C., Clark, Joseph I.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Malignant tumors of the salivary gland are rare entities that are treated primarily by surgical resection. For patients with recurrent or unresectable disease, options include radiation therapy or chemotherapy; however, responses are few and of short duration. Patients with metastatic disease have been treated with chemotherapy, but, again, response rates have been low and of short duration. Methods A 52‐year‐old man was seen with a mass on his tongue. A biopsy revealed adenocarcinoma of a minor salivary gland. Ten months after surgical resection, neck dissection, and radiation therapy, the patient was found to have metastatic disease to the lung. Chemotherapy was initiated with carboplatin and paclitaxel. Results The patient obtained a complete response after six cycles of carboplatin and paclitaxel. Conclusions The use of carboplatin and paclitaxel in the setting of metastatic salivary gland cancer is a viable option. © 2002 Wiley Periodicals, Inc. Head Neck 24: 406–410, 2002
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.10034